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Background: Oroxylum indicum has been used in traditional Ayurvedic medicine for the
prevention and treatment of several diseases and may have neuroprotective effects.
Purpose: Examine the effects of Oroxylum indicum on cognitive function in older adults
with self-reported cognitive complaints.
Study Design: Two-arm, parallel-group, 12-week, randomized, double-blind, placebo-
controlled trial.
Methods: Eighty-two volunteers received either 500 mg, twice daily of a standardized
Oroxylum indicum extract or placebo. Outcome measures included several computer-
based cognitive tasks, the Control, Autonomy, Self-Realization, and Pleasure scale
(CASP-19), Cognitive Failures Questionnaire (CFQ), and the Montreal Cognitive
Assessment (MoCA). Changes in the concentration of brain-derived neurotrophic factor
(BDNF) were also examined.
Results: Compared to the placebo, Oroxylum indicum was associated with greater
improvements in episodic memory, and on several computer-based cognitive tasks such
as immediate word recall and numeric working memory, and a faster rate of learning
on the location learning task. However, there were no other significant differences
in performance on the other assessed cognitive tests, the MoCA total score, or
other self-report questionnaires. BDNF concentrations increased significantly in both
groups, with no statistically-significant between-group differences. Oroxylum indicum
was well tolerated except for an increased tendency for mild digestive complaints
and headaches.
Frontiers in Aging Neuroscience | www.frontiersin.org 1 August 2021 | Volume 13 | Article 728360
Lopresti et al. Oroxylum indicum on Cognitive Function
Conclusion: The results of this first human trial on the cognitive-enhancing effects of
Oroxylum indicum suggest that it is a promising herbal candidate for the improvement of
cognitive function in older adults with self-reported cognitive complaints.
Keywords: Oroxylum indicum, mild cognitive impairment, memory, brain-derived neurotrophic factor, randomized
clinical trial (RCT)
INTRODUCTION
Oroxylum indicum, also known as the Indian Trumpet tree,
is a small-to-medium size deciduous tree grown in the Asian
subcontinent and belonging to the Bignoniacae family. Most
parts of the tree have been used in traditional Ayurvedicmedicine
for the prevention and treatment of several diseases including
jaundice, arthritis and rheumatic problems, gastric ulcers, and
diabetes (Dinda et al., 2015). In Ayurveda,Oroxylum indicum is a
component contained in Chyawanprasha andDashamoolarishta,
two multi-herbal formulas commonly used in India (Dev et al.,
2010).
Compounds found in the different parts of the Oroxylum
indicum plant include flavonoids, alkaloids, tannins, glycosides,
saponins, phenols, and quinones (Dinda et al., 2015; Nik Salleh
et al., 2020). Flavonoids are the major storage components
and include baicalein, baicalein-7-O-diglucoside, chrysin,
and oroxylin-A (Chen et al., 2003; Yadav et al., 2013).
Oroxylum indicum and its compounds have several biological
activities including anticancer, antibacterial, anti-hyperglycemic,
cardioprotective, analgesic, antioxidant, and anti-inflammatory
effects (Dinda et al., 2015; Nik Salleh et al., 2020). Oroxylum
indicum is also reported to possess neuroprotective and
anti-epileptic activity (Rathod et al., 2016). In animal models,
oroxylin-A, a flavonoid in Oroxylum indicum, alleviated
hyperactivity, impulsivity, and attentional symptoms associated
with attention deficit hyperactivity disorder (Yoon et al., 2008;
Dela Pena et al., 2013; Yoon et al., 2013). In a mouse model, an
Oroxylum indicum extract also prevented cognitive impairment
caused by chemotherapy (Pondugula et al., 2020). Moreover,
in vitro studies conducted on oroxylin-A have demonstrated
that it inhibits dopamine re-uptake (Dela Pena et al., 2013;
Yoon et al., 2013), has an antagonistic effect on the gamma-
aminobutyric acid (GABA)-A receptor (Kim et al., 2008), and
stimulates the expression of brain-derived neurotrophic factor
(BDNF; Jeon et al., 2011, 2012). Dopamine and GABA are
neurotransmitters believed to play a role in attention, learning,
memory, and mood (Kulisevsky, 2000; Mohler, 2009); while
BDNF is a protein involved in neuronal survival and growth
(Lu et al., 2014). Neuroprotective effects from the flavonoids
baicalein (Sowndhararajan et al., 2017; Zhu et al., 2019) and
chrysin (Vedagiri and Thangarajan, 2016; Angelopoulou et al.,
2020) have also been identified.
Despite its widespread use in Ayurvedic medicine, there are
no human trials examining the effects of Oroxylum indicum
on cognitive function. Due to the promising findings from
animal studies and in vitro research demonstrating Oroxylum
indicum can influence several hormones, neurotransmitters, and
other biological processes associated with attention, learning,
and memory, the aim of this study was to examine its effect on




This was a two-arm, parallel-group, 12-week, randomized,
double-blind, placebo-controlled trial (Figure 1). As there has
been no previous human trial on Oroxylum indicum, a 12-week
treatment period was chosen to assess efficacy, safety, and
tolerability in participants. If supplementation is well tolerated
and has cognitive-enhancing benefits, it is expected that future
trials using a longer treatment duration will be undertaken.
The trial protocol was approved by the Human Research Ethics
Committee at the National Institute of Integrative Medicine
(approval number 0070E_2020) and was prospectively registered
with the Australian and New Zealand Clinical Trials Registry
(Trial ID. ACTRN12620000800921). As there has been no
previous trial examining the effects of Oroxylum indicum on
cognition, an estimate of effect size could not be determined.
However, in previous herbal, cognition trials utilizing the
COMPASS as an outcome measure, sample sizes of 70–80 have
been used (Kennedy et al., 2019; Wightman et al., 2020).
Therefore, we aimed to recruit at least 80 people to determine
whether Oroxylum indicum produced a similar effect on
COMPASS cognitive tasks.
Recruitment and Randomization
Participants were recruited via social media advertisements
throughout Western Australia between September and
November 2020. Interested volunteers were directed to a
website page that provided details about the trial and a link to
complete an online screening form for self-reported memory
problems; medication use; history of medical or psychiatric
disorders; alcohol, nicotine, and other drug use; and supplement
and vitamin intake. To assess the severity of depressive
symptoms, respondents also completed the Geriatric Depression
Scale—Short Form (Van Marwijk et al., 1995). If considered
likely eligible, volunteers participated in a telephone interview
comprising a structured series of questions to further assess
their eligibility and to obtain further demographic details.
During this telephone assessment, a researcher administered the
Australian adaptation of the Modified Telephone Interview for
Cognitive Status (TICS-M; Bentvelzen et al., 2019). The TICS-M
is validated against the Mini-Mental State Examination and
other cognitive screens and has good sensitivity in detecting
mild cognitive impairment (De Jager et al., 2003). Suitable
participants were then required to complete an online consent
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FIGURE 1 | Systematic illustration of study design. BDNF, Brain-derived neurotrophic factor; CASP-19, Control, Autonomy, Self-Realization, and Pleasure; CFQ,
Cognitive Failures Questionnaire; COMPASS, Computerized Mental Performance Assessment System; MoCA, Montreal Cognitive Assessment.
form and attend a face-to-face assessment located at our offices
approximately 3–7 days after the phone interview. During the
in-person assessment, respondents completed electronic versions
of the Control, Autonomy, Self-Realization, and Pleasure
questionnaire (CASP-19) and Cognitive Failures Questionnaire
(CFQ). A researcher also administered the Montreal Cognitive
Assessment (MoCA) and participants completed several tasks
from the Computerized Mental Performance Assessment System
(COMPASS; see Table 1).
Eligible and consenting participants were randomly allocated
to one of two groups (Oroxylum indicum extract or placebo).
To ensure sequence concealment, a randomization calculator1
was used with the randomization structure comprising eight
randomly permuted blocks, containing 10 participants per block.
The participant identification number was assigned based on the
order of participant enrolment in the study. All capsules were
packed in identical bottles labeled by two intervention codes
(held by the capsule manufacturer until final data collection).
1http://www.randomization.com
Participants and study investigators were blind to treatment
group allocation until all outcome data were collected. To
compensate participants for their time and travel costs a $30 gift
voucher was provided at the end of each face-to-face assessment.
Participants allocated to the placebo condition were also offered
a free 12-week supply of Oroxylum indicum extract capsules.
Participants
Inclusion Criteria
Male and female participants aged 60–85 years, with
self-reported impairments in memory or cognitive skills
were recruited for this trial as measured by an affirmative
response to one of the following questions: (1) Do you feel your
memory and thinking has become worse over the past 2–3 years?
or; (2) Are you concerned about your decline in memory and
thinking? Volunteers had a body mass index (BMI) between
18 and 35 and scored between the 10th and 40th percentile
for their age, education, and sex on the Australian adaptation
of the Telephone Interview for Cognitive Status-modified
version (TICS-M). Participants had no plan to commence new
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TABLE 1 | COMPASS tasks completed.
Task Description Scoring
Word presentation
A list of words was displayed on the screen, one word at a time. In this case, 15 words were
presented with a display time of 1 s and an inter-stimulus interval of 1 s
–
Immediate word recall Participants were given 60 s to write down the words that were presented. % of words correctly recalled
Picture presentation A series of 20 photographic images were displayed on the screen, one at a time. The images were




A 5 × 5 grid was presented in which 10 of the squares contained pictures of objects. The
participant was asked to remember the locations of these objects within the grid. On five occasions,
they were then presented with a blank 5 × 5 grid with the objects displayed to the right of the
screen and were required to relocate the objects to the correct location.
Displacement score
Simple reaction time On 50 occasions, an upwards pointing arrow was displayed on the screen at irregular intervals.
Participants responded as quickly as possible when they saw the arrow appear.
Reaction time (ms)
Choice reaction time Arrows pointing left and right appeared on the screen at irregular intervals. The participant was
required to indicate the direction of the arrow as quickly as possible whenever an arrow was
displayed, by pressing the corresponding button. In this task, 50 stimuli were presented.
Accuracy (%) and reaction time
for the correct responses (ms)
Numeric working
memory
A series of numbers was displayed on the screen, one at a time. Participants were required to
memorize these numbers. Once the series was complete, numbers were displayed one at a time,
and participants were required to indicate if each number was presented in the previous list or not.
In this task, three trials were completed with five target numbers in each trial.
Accuracy (%) and reaction time
for the correct responses (ms)
Delayed word recall Participants were instructed to write down the words that were presented to them at the beginning
of the assessment. They were given 60 s to complete the task
% of words correctly recalled
Delayed word
recognition
All target words that were shown during the word presentation task plus an equal number of decoys
were displayed on the screen one at a time. Participants indicated if they remembered seeing the
word earlier or not.
Accuracy (%) and reaction time
for the correct responses (ms)
Delayed picture
recognition
All target pictures shown during the picture presentation task plus an equal number of decoys were
displayed on the screen one at a time. Participants indicated if they remembered seeing the picture
earlier or not.
Accuracy (%) and reaction time
for the correct responses (ms)
Delayed location
recognition
A blank 5 × 5 grid was presented with the same objects to the right of the screen as shown in the
computerized location learning task. The participant was required to relocate the objects to the
position on the grid presented during the computerized locations learning task without seeing them
again.
Displacement score
treatments over the study period, were fluent in English and
consented (via an online consent form) to all pertinent aspects
of the trial.
Exclusion Criteria
Participants were ineligible to participate in the study if
they were diagnosed with dementia (based on the revised
National Institute on Aging-Alzheimer’s Association criteria),
and suffered from medical conditions including but not limited
to: uncontrolled hypertension; myocardial infarction, unstable
or severe cardiovascular disease including angina or congestive
heart disease in the last year; bleeding disorders; type I diabetes;
glaucoma; chronic renal failure; chronic hepatic disease; severe
pulmonary disease; gastrointestinal disease requiring regular
use of medications; gallbladder disease/gallstones/biliary disease;
neurodegenerative or neurological disease. Participants were
also ineligible for the study if they were diagnosed with a
significant psychiatric disorder, including schizophrenia, bipolar
disorder, obsessive-compulsive disorder, personality disorder, or
scored greater than 5 on the Geriatric Depression Scale, Short
Form (indicating moderate-to-severe depression). A history of
stroke, seizures, or head injury (with loss of consciousness),
any major surgeries over the last year, significant hearing loss
that may impact the person’s ability to complete the phone
assessment, regular medication intake including anti-coagulant
drugs, anti-cholinergics, acetylcholinesterase inhibitors, and
steroid medications, and any change in medication in the last
3 months or an expectation to change during the study period
also resulted in exclusion from the study. People taking vitamins
or herbal supplements that were reasonably expected to influence
study measures, a current or 12-month history of illicit drug
abuse, and alcohol intake greater than 14 standard drinks per
week were also ineligible to participate in the study.
Interventions
Oroxylum indicum and placebo capsules were identical in
appearance, beingmatched for color coating, shape, and size. The
active ingredient, supplied by Sabinsa Corporation, comprised
a standardized Oroxylum indicum extract, Sabroxy R©, which is
a methanolic extract of the bark of Oroxylum indicum. The
active treatment contained 500 mg of Sabroxy R©, which is
standardized to contain 10% oroxylin-A, 6% chrysin, and 15%
baicalein. The placebo capsules contained the same excipients as
the active capsules (cellulose powder, lactose, and magnesium
stearate). All participants were instructed to take one capsule,
twice daily (morning and evening), with or without food, for
12 weeks. Capsule adherence was assessed by asking participants
to provide a capsule count every 4 weeks. Treatment blinding
was assessed by asking participants to predict group allocation
(placebo, Oroxylum indicum, or unsure) at the end of the study.
All capsules were provided to participants with directions for use
provided on capsule bottles. An information sheet about capsule
intake and what to do if a dose was missed was also given to
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participants. This information was also conveyed to participants
during their initial in-person assessment.
Outcome Measures
Primary Outcome Measure
Computerized Mental Performance Assessment System
(COMPASS)
The COMPASS (Northumbria University, Newcastle upon
Tyne, UK) is a software application for the presentation of
computerized standard and novel cognitive tasks that assess
episodic memory and speed of response. Results on the
COMPASS are sensitive to dietary interventions and nutritional
supplementation (Cox et al., 2014; Dodd et al., 2015; Kennedy
et al., 2017). The cognitive tasks used in this study are detailed
in Table 1. The COMPASS was completed at baseline and
week 12. At each assessment, participants completed a brief
practice session to familiarize themselves with the necessary tasks
and then completed the full COMPASS assessment as detailed
in Table 1. Since the goal of this study was to examine the
chronic effects of supplementation, participants were asked to
not take their morning study medication on the day of his/her
final assessment. Moreover, they arrived for testing in a fasting
state and did not consume any morning caffeinated beverage.
Participants were also asked to avoid consuming any alcohol
on the evening before testing. All assessments occurred in the
morning between 8 and 11 am, with the time of testing at
baseline and week 12 occurring at approximately the same time
for each participant. When participants arrived for testing, a
blood sample was collected, they consumed a breakfast bar
and non-caffeinated herbal tea (optional) while they completed
their online questionnaires, and then completed the COMPASS
testing.
Secondary Outcome Measures
Control, Autonomy, Self-realization, and Pleasure
(CASP-19)
The CASP-19 is a measure of well-being developed for older
people, spanning four domains of control, autonomy, self-
realization, and pleasure (Hyde et al., 2003). Items on this
19-item questionnaire are rated on a 4-point Likert scale ranging
from never to often, with higher scores indicating better well-
being. In studies on community-dwelling older-age adults, and
older adults with dementia, the CASP-19 demonstrated sound
psychometric properties (Sim et al., 2011; Stoner et al., 2019). The
CASP-19 was completed at baseline, and weeks 4, 8, and 12.
Cognitive Failures Questionnaire (CFQ)
The 25-item CFQ assesses the frequency with which people
experienced cognitive failures, such as absent-mindedness in
everyday life, slips, and errors of perception, memory, and
motor functioning (Broadbent et al., 1982). The CFQ has
good psychometric properties (Bridger et al., 2013) where
higher scores indicate worsened cognitive skills. The CFQ was
completed at baseline, and weeks 4, 8, and 12.
Montreal Cognitive Assessment (MoCA)
The MoCA is a validated measure of mild cognitive impairment
assessing short–term memory, visuospatial abilities, executive
function, attention, concentration, working memory, language,
and orientation to time and place (Nasreddine et al., 2005). The
MoCA has good psychometric properties and is regularly used as
a screening tool for mild cognitive impairment and Alzheimer’s
disease (Abd Razak et al., 2019; Bruijnen et al., 2020). In addition
to a total score, a memory index score (a measure of delayed
word recall) can also be calculated which has been shown to
be predictive of short-term conversion to Alzheimer’s disease
(Julayanont et al., 2014). The MoCA was completed at baseline
and week 12.
Brain-Derived Neurotrophic Factor (BDNF)
BDNF is a key molecule involved in plastic changes related
to learning and memory. Changes in BDNF expression are
associated with both normal and pathological aging, psychiatric
diseases, and the regulation of plastic changes in the adult brain
(Miranda et al., 2019). Blood samples for BDNF analysis were
collected at baseline and week 12.
Blood samples were collected in EDTA tubes after an
overnight fast. All samples were collected between 9 and 11 am.
EDTA tubes were centrifuged at 1,500× g for 15 min and
the plasma was stored in a −80-degree freezer until later
analysis. On the day of assay, serum samples were thawed
and mature BDNF measured using the commercially available
RayBio human BDNF enzyme-linked immunosorbent assay
(ELISA) kit (RayBiotech Life, Peachtree Corners, GA, USA)
according to the manufacturer instructions. Serum samples
were diluted 1:250 prior to assay. The BDNF ELISA is an
indirect sandwich kit in which BDNF from the test sample
is captured by an immobilized BDNF antibody and after
several washes, a biotinylated anti-human BDNF antibody is
added. After washing away unbound biotinylated antibody
horseradish peroxidase conjugated streptavidin was added.
The wells were again washed before the addition of TMB
substrate. The amount of BDNF in the test sample is
directly proportional to developed color measured by optical
density.
Adverse Events
Tolerability and safety of capsule intake by participants were
assessed at weeks 4, 8, and 12 via an online question querying
adverse effects that were believed to be associated with capsule
intake. Participants were also requested to contact the researchers
immediately if any adverse effects were experienced.
Statistical Analysis
For baseline data, an independent samples t-test was used to
compare group data for continuous variables, and a Pearson’s
Chi-square test was used to compare categorical data. Three
separate general linear model multivariate ANOVAs were
conducted to assess the change in scores on the self-report
questionnaires (CASP-19 sub-scale scores and CFQ total score,
weeks 0, 4, 8, and 12); and episodic memory and speed of
performance (baseline and week-12 scores). Medication and
nutraceutical use were included as covariates for the analysis of
episodic memory and speed of performance. Episodic memory
comprised scores on the following measures: immediate word
recall (percentage correct), delayed word recall (percentage
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correct), location learning recall (displacement score), word
recognition (percentage correct), picture recognition (percentage
correct), numeric working memory (percentage correct), and
MoCA memory index score. To maintain consistency in
scoring (i.e., increased scores indicate improvements in cognitive
performance), displacement scores on the location learning
recall task were converted from positive to negative numbers
with a maximum score of 0. Speed of performance comprised
the following measures: simple reaction time, choice reaction
time, numeric working memory reaction time, and picture
recognition reaction time (reaction time in ms of correct
responses). These cognitive skill categorizations are consistent
with other studies that have used the COMPASS as an
outcome measure (Kennedy et al., 2019; Wightman et al.,
2020). Univariate ANOVAs were also conducted to examine
between-group differences in changes in the MoCA total
score, MoCA memory index score, and BDNF concentrations
(medication and nutraceutical use were entered as covariates).
To avoid problems of collinearity, a multivariate analysis
was not conducted on the two MoCA scores. As a measure
of visuospatial learning, a time × trial × group, repeated-
measures ANOVA was conducted on the displacement scores
(trials 1–5) on the location learning task. A Cohen’s d
effect size was also calculated for all individual outcome
measures. The normality of residuals was assessed by the
visual inspection of Q-Q plots and analysis of skewness and
kurtosis. This demonstrated that most self-report data and
BDNF concentrations were normally distributed. However, as
COMPASS scores were not normally distributed, the data
were winsorized whereby scores greater than three standard
deviations from the mean were replaced with the next highest
score. Winsorizing is a robust method to normalize data
(Cleophas, 2015) and improved the normality of COMPASS
data. Where necessary, degrees of freedom were adjusted using
the Greenhouse-Geisser approach to correct for violations of
the sphericity assumption. Data from participants were included
in the analyses of self-report outcomes if questionnaire data
were obtained at week 4 (last observation carried forward
from week 4 for missing values). All data were analyzed
using SPSS (version 26; IBM, Armonk, NY, USA). The
critical p-value was set at p ≤ 0.05 for all analyses. Due
to the exploratory nature of this study, a correction to
the p-value due to multiple testing was not undertaken.
However, the type 1 error rate was minimized by using a
step-down analysis, whereby the multivariate ANOVA needed




Baseline Questionnaire and Demographic
Information
As detailed in Figure 1, from 132 people who completed
the initial online screening questionnaire, 45 individuals
did not meet the eligibility criteria, and five individuals
withdrew consent to participate in the study. 82 volunteers
participated in the study and 73 people completed the
study. Pre and post blood samples were collected from
70 participants. Details of participant demographic information
and baseline scores of the total recruited sample are detailed
in Tables 2, 3. Baseline demographic details, questionnaire
responses, and COMPASS test results were equivalent
in both groups. Nine participants withdrew from the
study. Reasons for withdrawal included no reason given
(n = 3), nausea/digestive complaints (n = 3), headaches
(n = 1), cold/flu (n = 1), and illness of a family member
(n = 1).
Outcome Measures
Primary Outcome Measure: COMPASS Scores
Changes in the COMPASS tasks and cognitive categories across
the two treatment groups and ANOVA significance levels
are detailed in Table 4. A general linear model multivariate
ANOVA revealed there was a statistically significant between-
group difference for episodic memory (F(7,59) = 2.77, p = 0.015)
but not speed of performance (F(5,61) = 1.03, p = 0.410).
Episodic memory [comprising the scores from immediate word
recall (percentage correct), delayed word recall (percentage
correct), location learning recall (displacement score), word
recognition (percentage correct), picture recognition (percentage
correct), numeric working memory (percentage correct), and
MoCA memory index score] changed in the Oroxylum indicum
(F(7,28) = 2.38, p = 0.048) and placebo groups (F(7,27) = 2.94,
p = 0.020); however, increases were greater in the Oroxylum
indicum group.
An examination of individual COMPASS tasks revealed
greater increases in the correct responses in immediate word
recall (F(1,65) = 5.94, p = 0.018) and numeric working memory
(F(1,65) = 4.08, p = 0.048) in the Oroxylum indicum group
compared to the placebo group. There were no other statistically
significant between-group interactions on other COMPASS
tasks detailed in Table 4. In the location learning task
(comprising five learning trials), a repeated-measures ANOVA
time × group × trial analysis revealed a non-significant
interaction (F(4,210) = 1.21, p = 0.306; Table 5). However,
a statistically significant time × trial × group quadratic
component was identified indicating a faster rate of learning in
the Oroxylum indicum group compared to the placebo group at
week 12 and both groups at baseline (F(1,71) = 4.16, p = 0.045;
Figure 2).
Secondary Outcome Measures: CFQ and CASP-19
Sub-scale Scores
Changes in the self-report questionnaire scores across the two
treatment groups and repeated measures ANOVA significance
levels are detailed in Table 6. A multivariate analysis revealed
there was a statistically-significant time effect (F5,15 = 1.95,
p = 0.034) but no statistically-significant time × group
(F5,15 = 1.07, p = 0.402), or main effect for group (F5,15 = 0.12,
p = 0.987). An examination of individual scores revealed a
significant time × group effect for the CASP-19 control score
only (F3,209 = 3.45, p = 0.022). CASP-19 control scores increased
significantly in the Oroxylum indicum (F3,123 = 2.70, p = 0.048)
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TABLE 2 | Baseline demographics details and questionnaire scores.
Placebo (n = 40) Oroxylum indicum (n = 42) p-value
Age Mean 68.28 66.07 0.061a
SE 0.9 0.73
Gender Female (n) 28 33 0.374b
Male (n) 12 9
BMI Mean 25.88 26.38 0.541a
SE 0.59 0.56
Systolic blood pressure (mmHg) Mean 129.08 129.24 0.965a
SE 2.75 2.12
Diastolic blood pressure (mmHg) Mean 79.41 81.00 0.505a
SE 1.84 1.51
Marital status Single 9 16 0.125b
Married/de facto 31 26
Educational level Secondary 21 22 0.733b
Tertiary 11 14
Post-graduate 8 6
Exercise level (n) Never/rarely 5 7
1–2 times a week 8 3
3–5 times a week 15 12 0.180b
6+ times a week 12 20
Taking any prescription medication Yes 19 (47.50%) 21 (50.00%) 0.821b
Taking statin Yes 9 (22.50%) 7 (16.67%) 0.951b
Taking antidepressant Yes 6 (15.00%) 3 (7.14%) 0.255b
Taking proton pump inhibitor Yes 5 (12.50%) 3 (7.14%) 0.414b
Taking nutraceutical/ phytoceutical Yes 13 (32.50%) 11 (26.19%) 0.505b
MoCA total score Mean 25.18 24.60 0.301a
SE 0.41 0.37
MoCA Memory Index Score Mean 9.98 8.76 0.096a
SE 0.53 0.49
CFQ—Total score Mean 42.23 42.81 0.798a
SE 1.53 1.68
CASP-19—Control Mean 8.15 7.31 0.056a
SE 0.32 0.29
CASP-19—Autonomy Mean 10.68 10.52 0.748a
SE 0.38 0.40
CASP-19—Pleasure Mean 13.73 13.38 0.379a
SE 0.28 0.27
CASP-19—Self realization Mean 11.65 11.19 0.362a
SE 0.37 0.34
BDNF (ng/ml) Mean 952.00 863.33 0.104a
SE 41.32 33.61
a, independent samples t-test; b, chi-square analysis.
and there was a non-significant increase in the placebo group
(F2.5,95 = 2.64, p = 0.064).
Secondary Outcome Measure: MoCA
Changes in the MoCA scores across the two treatment groups
and repeated-measures ANOVA significance levels are detailed
in Tables 4 and 6. A repeated-measures ANOVA demonstrated
that there was no statistically significant change over time on the
MoCA total score (F1,71 = 1.01, p = 0.536) or the MoCA memory
index score (F1,71 = 3.23, p = 0.077).
Secondary Outcome Measure: BDNF Concentrations
Changes in the BDNF concentrations across the two treatment
groups and ANOVA significance levels are detailed in Table 6.
An ANOVA demonstrated that there was no statistically
significant between-group effect (F1,66 = 0.601, p = 0.441). In
both the Oroxylum indicum (F1,35 = 21.20, p < 0.001), and
placebo (F1,33 = 13.42, p = 0.001) groups, BDNF concentrations
increased over time. An exploratory analysis revealed that for
all participants (placebo and Oroxylum indicum) increases in
BDNF were not significantly correlated with improvements in
any outcome measure.
Intake of Supplements
At weeks 4 and 8, participants reported the number of remaining
capsules. Capsule bottles with remaining capsules were also
returned on the week 12 assessment. Based on these details, 93%
of participants took more than 80% of their capsules.
Efficacy of Participant Blinding
To evaluate the efficacy of condition concealment throughout
the study, participants were asked at the end of the study to
predict condition allocation (i.e., placebo, Oroxylum indicum, or
unsure). The efficacy of group concealment was high as 79% of
participants either incorrectly guessed treatment allocation or
were unsure.
Adverse Events
The frequency of self-reported adverse events is detailed in
Table 7. There was a tendency for more reported adverse events
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TABLE 3 | Baseline COMPASS scores.
Placebo (n = 40) Oroxylum indicum (n = 42) p-valuea
Immediate word recall (%) Mean 30.17 30.79 0.807
SE 1.85 1.77
Delayed word recall (%) Mean 15.00 16.98 0.483
SE 0.59 0.56
Systolic blood pressure (mmHg) Mean 129.08 129.24 0.965a
SE 2.04 1.94
Simple reaction time (ms) Mean 383.39 395.31 0.562
SE 15.05 13.93
Choice reaction time correct (%) Mean 97.50 98.24 0.223
SE 0.46 0.39
Choice reaction time for correct responses (ms) Mean 598.33 617.71 0.393
SE 17.03 14.87
Location learning trial 1 (displacement score) Mean 17.58 18.17 0.686
SE 1.07 0.99
Location learning trial 2 (displacement score) Mean 13.93 13.29 0.703
SE 1.10 1.25
Location learning trial 3 (displacement score) Mean 9.73 8.93 0.641
SE 1.24 1.17
Location learning trial 4 (displacement score) Mean 7.28 6.52 0.637
SE 1.08 1.15
Location learning trial 5 (displacement score) Mean 5.70 3.67 0.090
SE 0.86 0.82
Location learning recall (displacement score) Mean 7.10 5.81 0.387
SE 1.02 1.08
Numeric working memory correct (%) Mean 91.92 89.23 0.158
SE 1.17 1.46
Numeric working memory reaction time for correct responses (ms) Mean 1, 213.38 1, 355.70 0.069
SE 54.38 54.85
Word recognition correct (%) Mean 75.39 73.17 0.321
SE 1.50 1.61
Word recognition reaction time for correct responses (ms) Mean 1, 384.76 1, 572.62 0.133
SE 80.66 92.79
Picture recognition correct (%) Mean 93.19 95.67 0.057
SE 1.11 0.64
Picture recognition reaction time for correct responses (ms) Mean 1, 111.88 1, 130.42 0.757
SE 47.88 35.92
a, independent samples t-test.
in theOroxylum indicum group (n = 10) compared to the placebo
group (n = 6). No serious adverse events were reported by
participants, although one participant in the Oroxylum indicum
group withdrew due to reported ongoing headaches. In the
Oroxylum indicum group, the majority of adverse events were
digestion-related complaints (e.g., loose stools, nausea, and
bloating) and headaches. There were no reports of any adverse
events in 83% of participants in the Oroxylum indicum group
and 87% of participants in the placebo group. There were no
statistically significant between-group differences in changes in
systolic (p = 0.598) or diastolic (p = 0.700) blood pressure over
time. However, there was a trend for a greater weight loss in
the Oroxylum indicum group compared to the placebo group
(p = 0.058), with a weight loss of 1.1 kg and 0.13 kg, respectively,
from baseline to week 12.
DISCUSSION
In this 12-week randomized, double-blind, placebo-controlled
trial, supplementation with 500 mg twice daily of an Oroxylum
indicum extract (Sabroxy R©) in older adults with self-reported
memory complaints was associated with greater improvements
in episodic memory and several computer-based cognitive tasks
compared to the placebo. Episodic memory was assessed by
performance on several cognitive tasks including immediate
word recall, delayed word recall, location learning recall,
word recognition, picture recognition, numeric working
memory, and the MoCA memory index score. In relation
to changes in performance on individual tasks, there were
greater improvements in immediate word recall and numeric
working memory, and a faster rate of learning on the location
learning task in participants supplemented with Oroxylum
indicum compared to the placebo. However, there were no
other significant differences in performance on the other
assessed computer-based cognitive tests or the MoCA total
score. Moreover, there were no significant between-group
differences in changes in the CFQ, a self-report assessment of
cognitive and memory skills, and the CASP-19, a quality-
of-life measure for older adults. BDNF concentrations
increased significantly in both groups, with no statistically-
significant between-group differences. Oroxylum indicum
was well tolerated except for a tendency for more mild
digestive complaints and headaches. There was also a trend
suggesting minor weight loss, although this finding requires
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TABLE 4 | Change in COMPASS tasks.










Week 0 Week 12 Change p-valuea Week 0 Week 12 Change p-valuea
Measures of episodic memory
Immediate word recall
(%)
Mean 31.05 30.10 −0.95 0.548 31.58 37.02 5.44 0.029 0.52 0.018 0.015
SE 2.03 2.23 1.90 1.91 1.94 2.16
Delayed word recall
(%)
Mean 16.19 16.19 0.00 1.00 17.90 22.28 4.39 0.065 0.40 0.116
SE 2.23 2.10 1.62 2.08 1.78 1.97
Location learning recall
(displacement score)
Mean −7.54 −5.09 2.46 0.011 −5.87 −2.89 2.97 0.011 0.09 0.917
SE 1.13 0.89 0.93 1.09 0.70 1.00
Word recognition
correct (%)
Mean 75.69 75.98 0.29 0.888 72.97 77.39 4.41 0.136 0.30 0.273
SE 1.67 2.19 2.07 1.63 1.90 2.52
Picture recognition
correct (%)
Mean 92.64 95.57 2.93 0.010 95.57 96.50 0.93 0.226 0.39 0.182
SE 1.23 0.75 0.99 0.72 0.63 0.75
Numeric working
memory correct (%)
Mean 92.92 92.45 0.48 0.466 89.24 92.57 3.33 0.071 0.44 0.048
SE 1.11 1.03 0.93 1.60 1.07 1.46
MoCA—Memory index
score
Mean 10.29 10.09 −0.20 0.765 8.87 9.97 1.11 0.017 0.42 0.081
SE 0.54 0.51 0.55 0.50 0.54 0.46
Measures of speed of performance
Simple reaction time
(ms)
Mean 376.05 359.23 −16.82 0.220 388.74 365.77 −22.97 0.080 0.08 0.851 0.410




Mean 597.42 558.28 −39.15 0.014 604.73 573.83 −30.90 0.018 0.10 0.969





Mean 1,185.61 1,134.66 −50.95 0.145 1,347.41 1,190.91 −156.50 0.006 0.44 0.110





Mean 1,346.87 1,275.78 −71.09 0.297 1,542.72 1,389.05 −153.67 0.061 0.21 0.504





Mean 1,084.06 1,063.97 −20.08 0.878 1,101.60 1,055.86 −45.74 0.059 0.15 0.091




Mean 97.37 97.54 0.17 0.707 98.11 98.00 −0.11 0.803 0.11 0.603 NA
SE 0.50 0.42 0.45 0.43 0.33 0.43
aRepeated measures ANOVA; bANOVA with medication and supplement use entered as covariates.
verification in future clinical trials. In an in vitro trial,
oroxylin-A was shown to inhibit adipogenesis (Singh and
Kakkar, 2014).
Episodic memory refers to a neurocognitive system that
makes possible the conscious recollection of events as they
were previously experienced. It is a type of memory that
allows us to re-experience personal events from the past. It
involves the ability to learn, store, and retrieve information
about personal experiences that occur in daily life and is
believed to be influenced by neural components in the cortex
near the hippocampus (perirhinal cortex, the entorhinal cortex,
and the parahippocampal cortex), cortical and subcortical
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Time × trial × group
interaction
Time × trial × group
interaction (linear)
Time × trial × group
interaction
(quadratic)
Location learning trial 1
(displacement score)
Mean 17.57 15.71 18.16 16.63
SE 1.18 1.13 1.08 1.44
Location learning trial 2
(displacement score)
Mean 13.86 10.63 14.00 8.97
SE 1.17 1.16 1.31 1.03
Location learning trial 3
(displacement score)
Mean 9.97 7.66 9.29 3.66 0.306 0.993 0.045
SE 1.36 1.08 1.22 0.68
Location learning trial 4
(displacement score)
Mean 7.86 6.06 6.45 4.05
SE 1.19 1.12 1.13 0.88
Location learning trial 5
(displacement score)
Mean 5.97 4.71 3.74 2.18
SE 0.95 1.06 0.86 0.71
FIGURE 2 | Displacement scores in the COMPASS location learning task.
structures, and circuits within the medial temporal lobe
and hippocampus (Camina and Guell, 2017). Individuals
diagnosed with mild cognitive impairment and Alzheimer’s
disease typically have severe deficits in episodic memory
and dysfunction in the hippocampus (Nordahl et al., 2005).
There is research to suggest that impairment of episodic
memory may precede dementia by as much as 10 years
(Dannhauser et al., 2008).
Oroxylum indicum may positively influence episodic
memory viaseveral mechanisms. As measurements of plasma
BDNF concentrations in this study revealed there were no
significant between-group differences, other mechanisms of
action are speculated and require investigation in future trials.
Concentrations of plasma F2-isoprostane are a reliable index
of systemic oxidative stress (specifically lipid peroxidation)
and are elevated in adults with dementia (Bradley-Whitman
and Lovell, 2015). In a study on healthy older-age adults,
higher F2-isoprostane concentrations were associated with
significantly-worsened performance in episodic memory
(Downey et al., 2018). In fact, the detrimental effects of oxidative
stress on the cognitive decline have been regularly reported
in the literature (Salim, 2017; Kandlur et al., 2020). Oroxylum
indicum has strong antioxidant activity and its positive effects
on episodic memory may be viaits antioxidant effects and ability
to inhibit lipid peroxidation (Siriwatanametanon et al., 2010).
An inverse relationship between inflammation and cognitive
performance has been demonstrated in several studies (Sartori
et al., 2012). Although the results are inconsistent, higher
inflammation is associated with worsened episodic memory
(Simen et al., 2011; Tampubolon, 2016). The anti-inflammatory
effects associated with Oroxylum indicum and its components,
therefore, present another mechanism associated with its
cognitive-enhancing effects (Kalaivani and Mathew, 2009;
Tran et al., 2015; Lalrinzuali et al., 2016). The importance
of neurotransmitters in memory has been demonstrated
in several trials. For example, dopamine and GABA are
neurotransmitters believed to be associated with attention,
concentration, learning, memory, and mood (Kulisevsky,
2000; Mohler, 2009). In an acute study on older-age adults,
administration of the dopamine precursor levodopa led to a
dose-dependent benefit on episodic memory (Tampubolon,
2016). There is also accumulating evidence from human research
indicating that midbrain dopamine regions modulate episodic
memory, which occurs viainteractions with the hippocampus
(Shohamy and Adcock, 2010). Using H-magnetic resonance
spectroscopy, a relationship between GABA concentrations
in the medial prefrontal cortex and episodic memory has
been observed (Thielen et al., 2019). GABA-A receptors









TABLE 6 | Change in questionnaire scores and BDNF concentrations.












CASP-19—Control Mean 8.13 8.31 7.64 7.79 0.064 7.31 7.93 7.88 7.90 0.048 0.022b 0.50 0.987 0.034 0.402
SE 0.33 0.32 0.32 0.32 0.29 0.35 0.31 0.35
CASP-19—Autonomy Mean 10.69 10.87 11.08 10.90 0.669 10.52 11.00 10.98 11.21 0.179 0.645b 0.21
SE 0.39 0.35 0.36 0.37 0.40 0.38 0.38 0.32
CASP-19—Pleasure Mean 13.69 13.64 13.56 13.67 0.871 13.38 13.64 13.33 13.69 0.230 0.560b 0.24
SE 0.28 0.29 0.30 0.32 0.27 0.27 0.30 0.24
CASP-19—Self Realization Mean 11.56 11.56 11.56 11.82 0.600 11.19 11.48 11.40 11.76 0.170 0.806b 0.19
SE 0.37 0.38 0.37 0.39 0.34 0.39 0.33 0.33
CFQ—Total Mean 42.49 40.34 39.97 38.43 0.031 42.95 38.71 39.13 38.05 0.022 0.740b 0.09
SE 1.69 1.92 1.61 1.72 1.83 1.84 1.84 1.81
Placebo (n = 35) Oroxylum indicum (n = 38)
MoCA – total score Mean 25.29 − − 25.40 0.768e 24.79 − − 25.24 0.238e 0.525f 0.15 − − −
SE 0.45 − − 0.46 0.39 − − 0.41
Placebo (n = 34) Oroxylum indicum (n = 36)
BDNF (ng/ml) Mean 863.33 − − 1058.80 0.001e 953.02 − − 1211.58 <0.001e 0.441f 0.17 − − −
SE 33.61 − − 57.78 42.47 − − 54.63
aRepeated measures ANOVA within-group, time effects; brepeated-measures ANOVA, univariate time × group interaction; cPlacebo vs. Oroxylum indicum Cohen’s d effect size (based on changes in scores from baseline to week 12);
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TABLE 7 | Frequency of self-reported adverse events.
Placebo Oroxylum indicum
Headache 2
Loose stools 2 1
Nausea 2
Bloating 1 2
Skin rash 1 1
Increased thirst 2
Worsened sleep 1
Shortness of breath 1
Total number of 6 10
are believed to play a key role in cognitive processes as the
benzodiazepine receptor complex controls acetylcholine release
in the hippocampus, and it has been demonstrated that
GABA-A receptor antagonists increase acetylcholine release
in the hippocampus and basal forebrain (Moor et al., 1998;
Collinson et al., 2002; Vazquez and Baghdoyan, 2003). In vitro
studies conducted on oroxylin-A (a chemical compound in
Oroxylum indicum) have demonstrated that it can inhibit
dopamine re-uptake (Dela Pena et al., 2013; Yoon et al.,
2013), and has an antagonistic effect on the GABA-A receptor
(Kim et al., 2008).
The location learning task is a measure of visuospatial
learning and recall. Performance on this task is impaired in
older adults, adults with dementia, and stroke patients (Bucks
and Willison, 1997; Kessels et al., 2006). In this study, Oroxylum
indicum was associated with a faster rate of learning compared
to the placebo. How Oroxylum indicum influences spatial
learning requires further investigation; however, several potential
mechanisms are speculated. Because deficits in spatial memory
can occur after hippocampal damage (Kessels et al., 2004)
or lesions in the parietal cortex (Kessels et al., 2002; Schott
et al., 2019), Oroxylum indicum may affect neural activity in
these regions. Moreover, a relationship between visuospatial
memory and cholinergic and dopaminergic neurotransmitter
activity has been identified and, therefore, presents as another
mechanism of action (Meador et al., 1993; Winkler et al., 1995).
However, before definitive conclusions can be made on how
Oroxylum indicum affects visuospatial learning, more research
is required.
An interesting finding was the increase in plasma BDNF
concentrations over time in both groups, with no statistically-
significant between-group differences. Moreover, in this study,
increases in BDNF were not associated with improvements
in any cognitive outcome measure. Even though BDNF is
believed to have an important role in synaptic plasticity and
cognitive function, its measurement viahuman cognitive trials
has revealed inconsistent findings (Lu et al., 2014; Miranda
et al., 2019). However, low blood BDNF concentrations are
more consistently identified in adults with Alzheimer’s disease,
and less so in adults with mild cognitive impairment (Xie
et al., 2020). The recruitment of adults with self-reported
cognitive impairment in this study may, therefore, account
for these non-significant findings. Lifestyle habits and
genetic BDNF polymorphisms, which were not adequately
controlled for in this study, may also account for the
non-significant between-group findings. Approximately
50 percent of participants were taking a pharmaceutical
medication and 30% were taking a nutraceutical which may
have also impacted changes in BDNF over time. Moreover,
even though research suggests there is an association between
BDNF and cognitive function, there is limited evidence to
demonstrate increasing plasma BDNF is associated with
improvements in cognitive function. It is important to note
that a possible explanation for the increase in BDNF in
both groups may be due to recruitment timing. Participants
had baseline assessments conducted in early spring and
follow-up assessments in summer. This seasonal change may
be associated with increased physical activity and sunlight
exposure. Both physical activity (Szuhany et al., 2015)
and sunlight exposure (Molendijk et al., 2012) can increase
BDNF concentrations.
Limitations and Directions For Future
Research
Even though there were some positive results from this
first human trial examining the cognitive enhancing effect
of Oroxylum indicum on adults with self-reported cognitive
complaints, further research is required to validate and extend
these findings. In particular, it will be important to examine
the efficacy and safety of Oroxylum indicum administered
for longer periods, at different dosages, and on diverse
populations including older adults with formally diagnosed
mild cognitive impairment. It is important to note that the
mean age of participants was 68 years which is a relatively
young cohort. It is estimated that there is a prevalence of
8%, 10%, 15%, and, 25% of mild cognitive impairment in
the age ranges of 65–69 years, 70–74 years, 75–79 years,
and 80–84 years, respectively (Petersen et al., 2018). Since
advanced age is associated with a greater risk of mild
cognitive impairment and dementia, a greater emphasis on
adults of more advanced age will be important in future
trials to understand the effects of Oroxylum indicum on
neurocognitive performance.
In this study, cognitive-enhancing benefits were observed
after 3 months; however, it will be important to assess
the safety and efficacy of at least 6 months of intake in
older-age adults. Longer periods between assessments will
also reduce the confounding influence of learning effects
from multiple computer-based administrations. It is important
to note that approximately 50 percent of participants were
taking a pharmaceutical medication and 30% were taking
a nutraceutical. While these factors were controlled for in
the statistical analyses, it will be useful in future trials
to examine the effects of Oroxylum indicum on medicated
and unmedicated participants as cognitive performance and
biological mechanisms such as acetylcholinergic activity can
be modified by many medications and nutraceuticals (Colucci
et al., 2012; Ruxton et al., 2015). This trial was designed to
examine the chronic effects of Oroxylum indicum intake, so
its acute cognitive effects could not be determined. As the
12-week cognitive assessment was conducted in the morning,
approximately 12–16 h after the last intake of Oroxylum indicum
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(participants were instructed to not take the capsule on the
morning of the assessment), the effects observed were unlikely
to result from the acute administration of Oroxylum indicum.
A computer-based cognitive test and a self-report measure were
used to assess changes in cognitive performance. In future
trials, it will be important to include ecologically validated
outcome measures, particularly those associated with everyday
performance and independent living. Moreover, additional
outcome measures completed by clinicians and other informants
will help validate the findings from this study. Further objective
assessments including magnetic resonance imaging, single-
photon emission computed tomography, and blood collections
assessing markers of inflammation, oxidative stress, and other
relevant hormonal activity will also be useful. Even though
there were no between-group differences in changes in BDNF
concentrations, the effects of a longer intake of Oroxylum
indicum, and greater control on factors that may influence
BDNF, may be worthwhile.
In summary, the results of this first human trial on the
cognitive-enhancing effects of Oroxylum indicum suggest it
is a promising herbal candidate for the improvement of
cognitive function in older adults with self-reported cognitive
complaints. The 12-week intake of 500 mg twice daily of
an Oroxylum indicum extract (Sabroxy R©) was associated
with greater improvements in episodic memory and a faster
rate of learning on the location learning task (a measure
of visuospatial learning and recall). Oroxylum indicum was
well-tolerated with no significant adverse effects although there
was a tendency for increased reports of mild digestive complaints
and headaches. Future investigations will be important to
validate these findings and examine the safety and efficacy
of Oroxylum indicum on different populations, adults of
more advanced age, for longer treatment periods, at varying
doses, and in populations where pharmaceutical medication
use is more vigorously controlled. As Oroxylum indicum did
not increase BDNF concentrations more than the placebo,
further research into its potential mechanisms of action will
be important.
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